Mechanisms of Drug Resistance in AML

  • Michael Andreeff
  • Marina Konopleva
Part of the Cancer Treatment and Research book series (CTAR, volume 112)


The acute myelogenous leukemias (AML) are diverse in their clinical presentation, molecular, biological and immunological characteristics, and response to therapies. They encompass a wide spectrum of clinical features, developing slowly from myelodysplastic syndromes (MDS) or presenting with dramatic clinical features without prior warning, such as high circulating blast count resulting in leucostastis and bleeding, coagulopathies, cutaneous and organ infiltration, sepsis due to neutropenia, and anemia. Morphological classification was initially codified in the French-American-British (FAB) system1 and was recently modified in the World Health Organization (WHO) system.2 The leukemic transformation is believed to occur at an early stem cell level, based on the ability of CD34+38-leukemic cells to repopulate NOD/scid mice3 with the exception of acute promyelocytic leukemias (APL) that probably originate in CD34-33+cells. However, leukemic cells were recently reported to reside in the pre-CD34 “side-population” (SP) cell population,4 suggesting an even more primitive cell of origin


Acute Myeloid Leukemia Acute Promyelocytic Leukemia Acute Myelogenous Leukemia Multi Drug Resistance Complete Remission Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bennett JM, Catovsky D, Daniel MTet al.Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol, 33:451–458, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    Heaney ML, Golde DW. Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. Curr Oncol Rep, 2:140–143, 2000PubMedCrossRefGoogle Scholar
  3. 3.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med, 3:730–737, 1997.PubMedCrossRefGoogle Scholar
  4. 4.
    Wulf GG, Wang RY, Kuehnle Iet al.A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood, 98:1166–1173, 2001.PubMedCrossRefGoogle Scholar
  5. 5.
    Gilliland DG. Molecular genetics of human leukemia. Leukemia, 12:S7–12, 1998PubMedGoogle Scholar
  6. 6.
    Warrell RP Jr, Frankel SR, Miller WH Jret al.Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med, 324:1385–1393, 1991.PubMedCrossRefGoogle Scholar
  7. 7.
    Hayakawa F, Towatari M, Iida Het al.Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol, 101:521–528, 1998.PubMedCrossRefGoogle Scholar
  8. 8.
    Biethahn S, Alves F, Wilde Set al.Expression of granulocyte colony-stimulating factor-and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol, 27:885–894, 1999.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim SC, Hahn JS, Min YHet al.Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood, 93:3893–3899, 1999.PubMedGoogle Scholar
  10. 10.
    Milella M, Kornblau SM, Estrov Zet al.Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest, 108:851–859, 2001.PubMedGoogle Scholar
  11. 11.
    Delwel R, Salem M, Pellens Cet al.Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood, 72:1944–1949, 1988.PubMedGoogle Scholar
  12. 12.
    Park LS, Waldron PE, Friend Det al.Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood, 74:56–65, 1989.PubMedGoogle Scholar
  13. 13.
    White SM, Ball ED, Ehmann WCet al.Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia, 12:899–906, 1998.PubMedCrossRefGoogle Scholar
  14. 14.
    Pietsch T, Kyas U, Steffens Uet al.Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood, 80:1199–1206, 1992.PubMedGoogle Scholar
  15. 15.
    Piacibello W, Fubini L, Sanavio Fet al.Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood, 86:4105–4114, 1995.PubMedGoogle Scholar
  16. 16.
    Lisovsky M, Estrov Z, Zhang Xet al.Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood, 88:3987–3997, 1996.PubMedGoogle Scholar
  17. 17.
    Muroi K, Amemiya Y, Miura Y. Specificity of CD117 expression in the diagnosis of acute myeloid leukemia. Leukemia, 10:1048,1996.PubMedGoogle Scholar
  18. 18.
    Di Noto R, Lo PC, Schiavone EMet al.Stem cell factor receptor (c-kit, CDI17) is expressed on blast cells from most immature types of acute myeloid mallignancies but is also a characteristic of a subset of acute promyelocytic leukaemia. Br J Haematol, 92:562–564, 1996.PubMedCrossRefGoogle Scholar
  19. 19.
    Birg F, Courcoul M, Rosnet 0et al.Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, 80:2584–2593, 1992.PubMedGoogle Scholar
  20. 20.
    Carow CE, Levenstein M, Kaufmann SHet al.Expression of the hematopoietic growth factor receptor FLT3 (STK-1/F1k2) in human leukemias. Blood, 87:1089–1096, 1996.PubMedGoogle Scholar
  21. 21.
    Yokota S, Kiyoi H, Nakao Met aLInternal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11:1605–1609, 1997.PubMedCrossRefGoogle Scholar
  22. 22.
    Cioffi JA, Shafer AW, Zupancic TJet al.Novel B219/0B receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nature Med, 2:585–589, 1996.PubMedCrossRefGoogle Scholar
  23. 23.
    Tartaglia LA, Dembski M, Weng Xet al.Identification and expression cloning of a leptin receptor, OB-R. Cell, 83:1263–1271, 1995.PubMedCrossRefGoogle Scholar
  24. 24.
    Konopleva M, Mikhail A, Estrov Zet al.Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and antiapoptotic activities. Blood, 93:1668–1676, 1999.PubMedGoogle Scholar
  25. 25.
    Estey E, Thall P, Kantarjian Het al.Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia, 11:1661–1664, 1997.PubMedCrossRefGoogle Scholar
  26. 26.
    Bennett BD, Solar GP, Yuan JQet al.A role for leptin and its cognate receptor in hematopoiesis. Curr Biol, 6:1170–1180, 1996.PubMedCrossRefGoogle Scholar
  27. 27.
    Laharrague P, Larrouy D, Fontanilles AMet al.High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J, 12:747–752, 1998.PubMedGoogle Scholar
  28. 28.
    Griffin JD, Young D, Herrmann Fet al.Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood, 67:1448–1453, 1986.PubMedGoogle Scholar
  29. 29.
    Bettelheim P, Valent P, Andreeff Met al.Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 77:700–711, 1991.PubMedGoogle Scholar
  30. 30.
    Buchner T, Hiddemann W, Wormann Bet al.The role of GM-CSF in the treatment of acute myeloid leukemia. Leukemia Lymph, 11:21–24, 1993.CrossRefGoogle Scholar
  31. 31.
    Estey EH, Thall PF, Pierce Set al.Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood, 93:2478–2484, 1999.PubMedGoogle Scholar
  32. 32.
    Estey E, Thall PF, Kantarjian Het al.Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GMCSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood, 79:2246–2255, 1992.PubMedGoogle Scholar
  33. 33.
    Bai A, Kojima H, Hori Met al.Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol, 27:259–265, 1999.PubMedCrossRefGoogle Scholar
  34. 34.
    Fong GH, Rossant J, Gertsenstein Met al.Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376:66–70, 1995.PubMedCrossRefGoogle Scholar
  35. 35.
    Fiedler W, Graeven U, Ergun Set al.Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89:1870–1875, 1997.PubMedGoogle Scholar
  36. 36.
    Shalaby F, Rossant J, Yamaguchi TPet al.Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376:62–66, 1995.PubMedCrossRefGoogle Scholar
  37. 37.
    Shalaby F, Ho J, Stanford WLet al.A requirement for Flkl in primitive and definitive hematopoiesis and vasculogenesis. Cell, 89:981–990, 1997.PubMedCrossRefGoogle Scholar
  38. 38.
    Kennedy M, Firpo M, Choi Ket al.A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature, 386:488–493, 1997.PubMedCrossRefGoogle Scholar
  39. 39.
    Ziegler BL, Valtieri M, Porada GAet al.KDR receptor: a key marker defining hematopoietic stem cells. Science, 285:1553–1558, 1999.PubMedCrossRefGoogle Scholar
  40. 40.
    Fielder W, Graeven U, Ergun Set al.Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia, 11:1234–1237, 1997.PubMedCrossRefGoogle Scholar
  41. 41.
    Ratajczak MZ, Ratajczak J, Machalinski Bet al.Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br J Haematol, 103:969–979, 1998.PubMedCrossRefGoogle Scholar
  42. 42.
    Perez-Atayde AR, Sallan SE, Tedrow Uet al.Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Amer J Pathol, 150:815821, 1997.Google Scholar
  43. 43.
    Aguayo A, Estey E, Kantarjian Het al.Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94:3717–3721, 1999.PubMedGoogle Scholar
  44. 44.
    Campbell JJ, Qin S, Bacon KBet al.Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J Cell Biol, 134:255–266, 1996.PubMedCrossRefGoogle Scholar
  45. 45.
    Graham GJ, Wright EG, Hewick Ret al.Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature, 344:442–444, 1990.PubMedCrossRefGoogle Scholar
  46. 46.
    Mohle R, Bautz F, Rafli Set al.The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood, 91:4523–4530, 1998.PubMedGoogle Scholar
  47. 47.
    Nagasawa T, Hirota S, Tachibana Ket al.Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 382:635–638, 1996.PubMedCrossRefGoogle Scholar
  48. 48.
    Ma Q, Jones D, Borghesani PRet al.Impaired B-Iymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA, 95:9448–9453, 1998.PubMedCrossRefGoogle Scholar
  49. 49.
    Patel VP, Kreider BL, Li Yet al.Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med, 185:1163–1172, 1997.PubMedCrossRefGoogle Scholar
  50. 50.
    Dexter TM. Regulation of hemopoietic cell growth and development: experimental and clinical studies. Leukemia, 7:469–474, 1989.Google Scholar
  51. 51.
    Bendall LJ, Daniel A, Kortlepel Ket al.Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol, 22:1252–1260, 1994.PubMedGoogle Scholar
  52. 52.
    Bendall LJ, Kortlepel K, Gottlieb DJ. Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta-1 and beta-2 integrin mechanisms. Blood, 82:3125–3132, 1993.PubMedGoogle Scholar
  53. 53.
    Tanaka Y, Albelda SM, Horgan KJet al.CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med, 176:245253, 1992.Google Scholar
  54. 54.
    Kinashi T, Springer TA. Steel factor and c-kit regulate cell-matrix adhesion. Blood, 83:1033–1038, 1994.PubMedGoogle Scholar
  55. 55.
    Manabe A, Coustan-Smith E, Behm FGet al.Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood, 79:2370–2377, 1992.PubMedGoogle Scholar
  56. 56.
    Kumagai M, Manabe A, Pui CHet al.Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest, 97:755–760, 1996.PubMedCrossRefGoogle Scholar
  57. 57.
    Konopleva M, Konoplev S, Hu Wet al.Stroma cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia, In Press, 2002.Google Scholar
  58. 58.
    Hu ZB, Minden MD, McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood, 92:1768–1775, 1998.PubMedGoogle Scholar
  59. 59.
    Campos L, Sabido 0, Rouault JPet al.Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, 84:595–600, 1994.PubMedGoogle Scholar
  60. 60.
    Konopleva M, Tani A, Estrov Zet al.Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize AML to cytosine-arabinoside, and induce apoptosis independent of other anti-apoptotic proteins. Blood, 95:3929–3938, 2000.PubMedGoogle Scholar
  61. 61.
    McNiece IK, Stewart FM, Deacon DMet al.Detection of a human CFC with a high proliferative potential. Blood, 74:609–612, 1989.PubMedGoogle Scholar
  62. 62.
    Ailles LE, Gerhard B, Kawagoe Het al.Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood, 94:1761–1772, 1999.PubMedGoogle Scholar
  63. 63.
    Peled A, Petit I, Kollet 0et al.Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science, 283:845–848, 1999.PubMedCrossRefGoogle Scholar
  64. 64.
    Konopleva M, Monaco G, Zhao Set al.Engraftment potential of AML progenitors into NOD/scidmice is dependent on baseline CXCR4 expression. Blood, 94:1656, 1999.Google Scholar
  65. 65.
    Zhou S, Schuetz JD, Bunting KDet al.The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med, 7:1028–1034, 2001.PubMedCrossRefGoogle Scholar
  66. 66.
    Matthews DC. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia, 12:S33, 1998.PubMedGoogle Scholar
  67. 67.
    Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol, 16:3691–3710, 1998.PubMedGoogle Scholar
  68. 68.
    Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res, 4:1421–1428, 1998.PubMedGoogle Scholar
  69. 69.
    Bernstein ID, Singer JW, Andrews RGet al.Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest, 79:1153–1159, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Jurcic JG, DeBlasio A, Dumont Let al.Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Blood, 90:416a, 1997.Google Scholar
  71. 71.
    Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol, 36:2–8, 1999.PubMedGoogle Scholar
  72. 72.
    Sievers EL, Appelbaum FR, Spielberger RTet al.Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93:3678–3684, 1999.PubMedGoogle Scholar
  73. 73.
    Sievers E, Larson RA, Estey Eet al.Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse. Blood, 96:613a, 1998.Google Scholar
  74. 74.
    Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol, 14:1383–1400, 1996.PubMedGoogle Scholar
  75. 75.
    Jurcic JG, McDevitt MR, Sgouros Get al.Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-21-HuM195 (anti-CD33). Blood, 90:504a, 1997.Google Scholar
  76. 76.
    Mathews DC, Appelbaum FR, Eary JFet al.Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemias and myelodysplastic syndrome. Blood, 90:417a, 1997.Google Scholar
  77. 77.
    Gros P, Ben Neriah YB, Croop JMet al.Isolation and expression of a complementary DNA that confers multidrug resistance. Nature, 323:728–731, 1986.PubMedCrossRefGoogle Scholar
  78. 78.
    Cole SP, Bhardwaj G, Gerlach JHet al.Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258:1650–1654, 1992.PubMedCrossRefGoogle Scholar
  79. 79.
    Doyle LA, Yang W, Abruzzo LVet al.A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 95:15665–15670, 1998.PubMedCrossRefGoogle Scholar
  80. 80.
    Scheffer GL, Wijngaard PL, Flens MJet al.The drug resistance-related protein LRP is the human major vault protein. Nature Med, 1:578–582, 1995.PubMedCrossRefGoogle Scholar
  81. 81.
    O’Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer, 32A:967–978, 1996.PubMedCrossRefGoogle Scholar
  82. 82.
    Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer, 32A:958–966, 1996.PubMedCrossRefGoogle Scholar
  83. 83.
    Andreeff M, Jiang S, Zhang Xet al.Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia, 13:1881–1892, 1999.PubMedCrossRefGoogle Scholar
  84. 84.
    Kantharidis P, El Osta A, deSilva Met al.Altered methylation of the human MDRI promoter is associated with acquired multidrug resistance. Clin Cancer Res, 3:2025–2032, 1997.PubMedGoogle Scholar
  85. 85.
    Smyth MJ, Krasovskis E, Sutton VRet al.The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspasedependent apoptosis. Proc Natl Acad Sci USA, 95:7024–7029, 1998.PubMedCrossRefGoogle Scholar
  86. 86.
    Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood, 93:1075–1085, 1999.PubMedGoogle Scholar
  87. 87.
    Rahman Z, Kavanagh J, Champlin Ret al.Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res, 4:2717–2721, 1998.PubMedGoogle Scholar
  88. 88.
    Bunting KD, Galipeau J, Topham Det al.Transduction of murine bone marrow cells with an MDRI vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood, 92:2269–2279, 1998.PubMedGoogle Scholar
  89. 89.
    Cole SP, Sparks KE, Fraser Ket al.Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res, 54:5902–5910, 1994.PubMedGoogle Scholar
  90. 90.
    Loe DW, Almquist KC, Deeley RGet al.Multidrug resistance protein (MRP)- mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem, 271:9675–9682, 1996.PubMedCrossRefGoogle Scholar
  91. 91.
    Leith CP, Kopecky KJ, Godwin Jet al.Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89:3323–3329, 1997.PubMedGoogle Scholar
  92. 92.
    Campos L, Guyotat D, Archimbaud Eet al.Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79:473–476, 1992.PubMedGoogle Scholar
  93. 93.
    Leith CP, Kopecky KJ, Chen IMet al.Frequency and clinical significance of the expression of the multidrug resistance proteins MDRI/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood, 94:1086–1099, 1999.PubMedGoogle Scholar
  94. 94.
    Filipits M, Suchomel RW, Zochbauer Set al.Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res, 3:1419–1425, 1997.PubMedGoogle Scholar
  95. 95.
    Ross DD, Doyle LA, Schiffer CAet al.Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia, 10:48–55, 1996.PubMedGoogle Scholar
  96. 96.
    Legrand 0, Simonin G, Perrot JYet al.Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood, 91:4480–4488, 1998.PubMedGoogle Scholar
  97. 97.
    List AF, Spier CS, Grogan TMet al.Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87:2464–2469, 1996.PubMedGoogle Scholar
  98. 98.
    Filipits M, Pohl G, Stranzl Tet al.Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91:1508–1513, 1998.PubMedGoogle Scholar
  99. 99.
    Kuss BJ, Deeley RG, Cole SPet al.Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet, 343:1531–1534, 1994.PubMedCrossRefGoogle Scholar
  100. 100.
    Goodell MA, Rosenzweig M, Kim Het al.Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nature Med, 3:1337–1345, 1997.PubMedCrossRefGoogle Scholar
  101. 101.
    Jackson KA, Mi T, Goodell MA. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA, 96:14482–14486, 1999.PubMedCrossRefGoogle Scholar
  102. 102.
    Ross DD, Karp JE, Chen TTet al.Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood, 96:365–368, 2000.PubMedGoogle Scholar
  103. 103.
    Michieli M, Damiani D, Ermacora Aet al.Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol, 106:92–99, 1999.PubMedCrossRefGoogle Scholar
  104. 104.
    Kolonias D, Podona T, Savaraj Net al.Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems. Anticancer Res, 19:1277–1283, 1999.PubMedGoogle Scholar
  105. 105.
    Andreeff M, Giles R, Sanchez-Williams Get al.Phase I study of Annamycin: A novel MDR-1 independent anthracycline in relapsed/refractory AML. Blood, 94:2256, 1999.Google Scholar
  106. 106.
    Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer, 32A:991–1001, 1996.PubMedCrossRefGoogle Scholar
  107. 107.
    Boesch D, Muller K, Pourtier-Manzanedo Aet al.Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res, 196:26–32, 1991.PubMedCrossRefGoogle Scholar
  108. 108.
    Hyafil F, Vergely C, Du VPet al.In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res, 53:4595–4602, 1993.PubMedGoogle Scholar
  109. 109.
    Sato W, Fukazawa N, Nakanishi 0et al.Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol, 35:271–277, 1995.PubMedCrossRefGoogle Scholar
  110. 110.
    Hofmann J, Gekeler V, Ise Wet al.Mechanism of action of dexniguldipine-HCI (B8509–035), a new potent modulator of multidrug resistance. Biochem Pharmacol, 49:603–609, 1995.PubMedCrossRefGoogle Scholar
  111. 111.
    Shudo N, Mizoguchi T, Kiyosue Tet al.Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res, 50:3055–3061, 1990.PubMedGoogle Scholar
  112. 112.
    Slate DL, Bruno NA, Casey SMet al.RS-33295–198: a novel, potent modulator of Pglycoprotein-mediated multidrug resistance. Anticancer Res, 15:811–814, 1995.PubMedGoogle Scholar
  113. 113.
    Germann UA, Shlyakhter D, Mason VSet al.Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs, 8:125–140, 1997.PubMedCrossRefGoogle Scholar
  114. 114.
    Kornblau SM, Estey E, Madden Tet al.Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol, 15:1796–1802, 1997.PubMedGoogle Scholar
  115. 115.
    Advani R, Saba HI, Tallman MSet al.Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood, 93:787–795, 1999.PubMedGoogle Scholar
  116. 116.
    Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res, 57:5246–5253, 1997.PubMedGoogle Scholar
  117. 117.
    List AF, Kopecky KJ, Willman CLet al.Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study. Blood, 92:321a, 1999.Google Scholar
  118. 118.
    Kobayashi H, Takemura Y, Wang FSet al.Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites. Int J Cancer, 81:944–950, 1999.PubMedCrossRefGoogle Scholar
  119. 119.
    Motomura S, Motoji T, Takanashi Met al.Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdrl) antisense oligonucleotides. Blood, 91:3163–3171, 1998.PubMedGoogle Scholar
  120. 120.
    Konopleva M, Andreeff M. Regulatory pathways in programmed cell death. Cancer Mol Biol, 6:1229–1260, 1999.Google Scholar
  121. 121.
    Kornblau S, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for hematological malignancies. Expert Opin Invest Drugs, 8:2027–2057, 1999.CrossRefGoogle Scholar
  122. 122.
    Friesen C, Herr I, Krammer PHet al.Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med, 2:574–577, 1996.PubMedCrossRefGoogle Scholar
  123. 123.
    Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia, 11:1833–1841, 1997.PubMedCrossRefGoogle Scholar
  124. 124.
    Eischen CM, Kottke TJ, Martins LMet al.Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90:935–943, 1997.PubMedGoogle Scholar
  125. 125.
    Wesselborg S, Engels IFI, Rossmann Eet al.Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 93:3053–3063, 1999.PubMedGoogle Scholar
  126. 126.
    Iijima N, Miyamura K, Itou Tet al.Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: Possible correlation with sensitivity to chemotherapy. Blood, 90:4901–4909, 1997.PubMedGoogle Scholar
  127. 127.
    Snell V, Clodi K, Zhao Set al.Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol, 99:618–624, 1997.PubMedCrossRefGoogle Scholar
  128. 128.
    Golstein P. Cell death: TRAIL and its receptors. Curr Biol, 7:R750–R753, 1997.PubMedCrossRefGoogle Scholar
  129. 129.
    Griffith TS, Chin WA, Jackson GCet al.Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol, 161:2833–2840, 1998.PubMedGoogle Scholar
  130. 130.
    Ogasawara J, Watanabe-Fukunaga R, Adachi Met al.Lethal effect of the anti-fas antibody in mice. Nature, 364:806–809, 1993.PubMedCrossRefGoogle Scholar
  131. 131.
    Snell V, Clodi K, Zhao Set al.Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Cancer, 99:624,1997.Google Scholar
  132. 132.
    Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature, 335:440–442, 1988.PubMedCrossRefGoogle Scholar
  133. 133.
    Traver D, Akashi K, Weissman ILet al.Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity, 9:47–57, 1998.PubMedCrossRefGoogle Scholar
  134. 134.
    Kornblau SM, Thall P, Estrov Zet al.The prognostic impact of bcl2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res, 5:1758–1766, 1999.PubMedGoogle Scholar
  135. 135.
    Konopleva M, Zhao S, Hu Wet al. The antiapoptotic genes Bcl-XL and Bc1–2 are overexpressed and contribute to chemoresistance of nonproliferating leukemic CD34+ cells. Br J Haematol, In Press, 2002.Google Scholar
  136. 136.
    Kaufmann SH, Karp JE, Svingen PAet al.Elevated expression of the apoptotic regulator Mc1–1 at the time of leukemic relapse. Blood, 91:991–1000, 1998.PubMedGoogle Scholar
  137. 137.
    Estrov Z, Thall PF, Talpaz Met al.Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood, 92:3090–3097, 1998.PubMedGoogle Scholar
  138. 138.
    Adida C, Berrebi D, Peuchmaur Met al.Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351:882–883, 1998.PubMedCrossRefGoogle Scholar
  139. 139.
    Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res, 58:1808–1812, 1998.PubMedGoogle Scholar
  140. 140.
    Kawasaki H, Altieri DC, Lu CDet a/.Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res, 58:5071–5074, 1998.PubMedGoogle Scholar
  141. 141.
    Li F, Ambrosini G, Chu EYet a/.Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396:580–584, 1998.PubMedCrossRefGoogle Scholar
  142. 142.
    Zha J, Harada H, Yang Eet al.Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3–3 not Bel-X. Cell, 87:619–628, 1996.PubMedCrossRefGoogle Scholar
  143. 143.
    del Peso L, Gonzalez-Garcia M, Page Cet a/.Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278:687–689, 1997.PubMedCrossRefGoogle Scholar
  144. 144.
    Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA, 95:7439–7444, 1998.CrossRefGoogle Scholar
  145. 145.
    Webb A, Cunningham D, Cotter Fet al.BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349:1137–1141, 1997.PubMedCrossRefGoogle Scholar
  146. 146.
    Dorai T, Goluboff ET, Olsson CAeta/. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res, 17:3307–3312, 1997.PubMedGoogle Scholar
  147. 147.
    Piche A, Grim J, Rancourt Cet a/.Modulation of Bcl-2 protein levels by an intracellular anti-Bc1–2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res, 58:2134–2140, 1998.PubMedGoogle Scholar
  148. 148.
    Cosulich SC, Worrall V, Hedge PJet al.Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol, 7:913–920, 1997.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Michael Andreeff
    • 1
  • Marina Konopleva
    • 1
  1. 1.Section of Molecular Hematology and Therapy Department of Blood and Marrow TransplantationThe University of Texas MD Anderson Cancer CenterTexasUSA

Personalised recommendations